NO781813L - Farmasoeytisk preparat og fremgangsmaate til dets fremstilling - Google Patents

Farmasoeytisk preparat og fremgangsmaate til dets fremstilling

Info

Publication number: NO781813L
Authority: NO; Norway
Prior art keywords: preparation; asa; sulfasalazine; active ingredient; pharmaceutically acceptable
Prior art date: 1977-05-25

Application number

NO78781813A

Other languages

English (en)

Norwegian (no)

Inventor

John Lawrence Worsley

Albert Chambers

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-05-25

Filing date

1978-05-24

Publication date

1978-11-28

1978-05-24 Application filed by Fisons Ltd filed Critical Fisons Ltd

1978-11-28 Publication of NO781813L publication Critical patent/NO781813L/no

Links

238000002360 preparation method Methods 0.000 title claims description 30
238000000034 method Methods 0.000 title claims description 19
239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
239000004480 active ingredient Substances 0.000 claims description 32
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 29
229960001940 sulfasalazine Drugs 0.000 claims description 29
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 29
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 14
150000001875 compounds Chemical class 0.000 claims description 12
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical group O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 6
159000000000 sodium salts Chemical class 0.000 claims description 6
241000792859 Enema Species 0.000 claims description 5
229960000265 cromoglicic acid Drugs 0.000 claims description 5
239000007920 enema Substances 0.000 claims description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 2
229940095399 enema Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 2
229960004963 mesalazine Drugs 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
208000035475 disorder Diseases 0.000 description 7
239000008187 granular material Substances 0.000 description 7
241000124008 Mammalia Species 0.000 description 5
239000000314 lubricant Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
-1 monocyclic nitrogen heterocyclic compounds Chemical class 0.000 description 5
206010002198 Anaphylactic reaction Diseases 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000036783 anaphylactic response Effects 0.000 description 4
208000003455 anaphylaxis Diseases 0.000 description 4
238000000576 coating method Methods 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000005557 antagonist Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079360 enema for constipation Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
DLKZWVIRKURGIR-UHFFFAOYSA-N 4-oxo-10-propyl-6,7,8,9-tetrahydrobenzo[g]chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1CCCCC1=C2 DLKZWVIRKURGIR-UHFFFAOYSA-N 0.000 description 2
YQCGBHBRCNCNLL-UHFFFAOYSA-N 5-(2-hydroxypropoxy)-4-oxo-8-propylchromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=CC=C2OCC(C)O YQCGBHBRCNCNLL-UHFFFAOYSA-N 0.000 description 2
VFFTVZUIDYJUQS-UHFFFAOYSA-N 5-hydroxy-4-oxo-10-propyl-6,7,8,9-tetrahydrobenzo[g]chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1CCCCC1=C2O VFFTVZUIDYJUQS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
206010036774 Proctitis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
SZGPJHJDNRNHIP-UHFFFAOYSA-N [Cr].[Na].[Na] Chemical compound [Cr].[Na].[Na] SZGPJHJDNRNHIP-UHFFFAOYSA-N 0.000 description 2
HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000002249 digestive system Anatomy 0.000 description 2
229940079593 drug Drugs 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000001993 wax Substances 0.000 description 2
NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000004300 Atrophic Gastritis Diseases 0.000 description 1
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
208000036495 Gastritis atrophic Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
125000005041 acyloxyalkyl group Chemical group 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
150000004777 chromones Chemical class 0.000 description 1
208000016644 chronic atrophic gastritis Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000000945 filler Substances 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
201000005298 gastrointestinal allergy Diseases 0.000 description 1
229940047135 glycate Drugs 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
208000009326 ileitis Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000002641 lithium Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical class NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
150000002943 palmitic acids Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000005041 phenanthrolines Chemical class 0.000 description 1
206010036784 proctocolitis Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000007964 xanthones Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

NO78781813A 1977-05-25 1978-05-24 Farmasoeytisk preparat og fremgangsmaate til dets fremstilling NO781813L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB2197577		1977-05-25
GB4910577		1977-11-25

Publications (1)

Publication Number	Publication Date
NO781813L true NO781813L (no)	1978-11-28

Family

ID=26255629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO78781813A NO781813L (no)	1977-05-25	1978-05-24	Farmasoeytisk preparat og fremgangsmaate til dets fremstilling

Country Status (14)

Country	Link
JP (1)	JPS5411236A (it)
AU (2)	AU3635578A (it)
CH (1)	CH633713A5 (it)
DE (1)	DE2822816A1 (it)
DK (1)	DK230578A (it)
FI (1)	FI781616A7 (it)
FR (1)	FR2391727A1 (it)
IL (1)	IL54770A (it)
IT (1)	IT7823716A0 (it)
LU (1)	LU79691A1 (it)
NL (1)	NL7805504A (it)
NO (1)	NO781813L (it)
NZ (1)	NZ187363A (it)
SE (1)	SE7805959L (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01299226A (ja) *	1988-05-27	1989-12-04	Seikagaku Kogyo Co Ltd	サラゾスルファピリジン腸溶顆粒

1978
- 1978-05-22 FI FI781616A patent/FI781616A7/fi not_active Application Discontinuation
- 1978-05-22 AU AU36355/78A patent/AU3635578A/en active Pending
- 1978-05-22 NL NL7805504A patent/NL7805504A/xx not_active Application Discontinuation
- 1978-05-22 AU AU36255/78A patent/AU518817B2/en not_active Expired
- 1978-05-23 IT IT7823716A patent/IT7823716A0/it unknown
- 1978-05-23 LU LU79691A patent/LU79691A1/xx unknown
- 1978-05-23 IL IL7854770A patent/IL54770A/xx unknown
- 1978-05-24 DK DK230578A patent/DK230578A/da not_active Application Discontinuation
- 1978-05-24 SE SE7805959A patent/SE7805959L/xx unknown
- 1978-05-24 DE DE19782822816 patent/DE2822816A1/de not_active Withdrawn
- 1978-05-24 NZ NZ187363A patent/NZ187363A/xx unknown
- 1978-05-24 NO NO78781813A patent/NO781813L/no unknown
- 1978-05-24 CH CH566778A patent/CH633713A5/fr not_active IP Right Cessation
- 1978-05-24 FR FR7815455A patent/FR2391727A1/fr active Granted
- 1978-05-25 JP JP6176678A patent/JPS5411236A/ja active Pending

Also Published As

Publication number	Publication date
JPS5411236A (en)	1979-01-27
AU3625578A (en)	1978-08-17
AU518817B2 (en)	1981-10-22
SE7805959L (sv)	1978-11-26
DK230578A (da)	1978-11-26
DE2822816A1 (de)	1978-11-30
NZ187363A (en)	1984-12-14
FI781616A7 (fi)	1978-11-26
FR2391727A1 (fr)	1978-12-22
IT7823716A0 (it)	1978-05-23
NL7805504A (nl)	1978-11-28
IL54770A0 (en)	1978-07-31
CH633713A5 (en)	1982-12-31
IL54770A (en)	1982-12-31
LU79691A1 (fr)	1979-02-02
AU3635578A (en)	1979-11-29
FR2391727B1 (it)	1980-06-06

Publication	Publication Date	Title
US4211777A (en)	1980-07-08	Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
EP3290415B1 (en)	2020-12-30	Opioid receptor ligands and methods of using and making same
JP6991993B2 (ja)	2022-01-13	痛覚過敏を治療する方法
NO175132B (no)	1994-05-30	Fremgangsmåte ved fremstilling av legemiddel inneholdende Dipyridamol eller Mopidamol og 0-acetylsalisyre samt deres fysiologisk fordragelige salter
JPS58219117A (ja)	1983-12-20	脳不全症の処置方法
EP3389656A1 (en)	2018-10-24	Combinations of opioid receptor ligands and cytochrome p450 inhibitors
JPH0148247B2 (it)	1989-10-18
NO781813L (no)	1978-11-28	Farmasoeytisk preparat og fremgangsmaate til dets fremstilling
CN101287730A (zh)	2008-10-15	哌嗪化合物的葡萄糖醛酸盐
WO2021027583A1 (zh)	2021-02-18	包含柠檬苦素类化合物和磺酰脲类药物的组合产品
US4088778A (en)	1978-05-09	Method for the treatment of hypertension
US4232012A (en)	1980-11-04	Composition
CN107011313B (zh)	2021-11-30	取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
CN114272250A (zh)	2022-04-05	环维黄杨星d及其衍生物在制备治疗抑郁症药物中的应用及制备的抗抑郁症药物
EP0713698B1 (en)	2002-04-03	Medical use of atypical beta-adrenoceptor agonists
CA2898279C (en)	2022-05-17	Use of phenoxypropylamine compounds to treat sleep disorders
CN105777520A (zh)	2016-07-20	一种新型查尔酮化合物Chalcone-1203及其组合物、制备方法和应用
JPS6069061A (ja)	1985-04-19	５―アミノサリチル酸―ｏ―サルフェートの塩
US4145438A (en)	1979-03-20	Method for treatment of eczema or psoriasis
CN108653292B (zh)	2019-05-24	一种化合物在治疗或预防高原病中的用途
US4870090A (en)	1989-09-26	Therapeutic agent for the treatment of disorders associated with cerebral ischemia
EP2599480A1 (en)	2013-06-05	Compounds for the treatment of influenza
CA1104931A (en)	1981-07-14	Pharmaceutical composition containing sulphasalazine
JP2009535395A (ja)	2009-10-01	９ａ−置換アザリド
JPH02237928A (ja)	1990-09-20	置換ベンズアミドより成る胃の自動運動性増進用薬剤